2024
Assessing the Effect of Changing the Average Hematocrit in Red Blood Cell (RBC) Units on the Post- Procedure Hematocrits of Patients Undergoing Erythrocytapheresis
Musante K, Roome L, Yurtsever N, Rinder H, Tormey C, Lee E. Assessing the Effect of Changing the Average Hematocrit in Red Blood Cell (RBC) Units on the Post- Procedure Hematocrits of Patients Undergoing Erythrocytapheresis. American Journal Of Clinical Pathology 2024, 162: s147-s147. DOI: 10.1093/ajcp/aqae129.326.Peer-Reviewed Original ResearchSickle cell diseaseRed blood cell unitsSickle cell disease patientsRed blood cellsPatient's HctRBC unitsTransfused RBC unitsRetrospective chart reviewTwo-sample t-testChart reviewAdverse eventsMedian numberPre-procedureProphylactic procedureCell diseasePatientsAcademic hospitalAverage hematocritAverage HctBlood cellsHctTransfusion servicesT-testQuality studiesHematocritPhenotypic and genotypic evaluation of bleeding diagnostic dilemmas: Two case studies
Gu S, Butt A, Schulz V, Rinder H, Lee A, Gallagher P, Hwa J, Bona R. Phenotypic and genotypic evaluation of bleeding diagnostic dilemmas: Two case studies. Blood Cells Molecules And Diseases 2024, 110: 102893. PMID: 39260211, DOI: 10.1016/j.bcmd.2024.102893.Peer-Reviewed Original ResearchInherited platelet disordersClinically significant bleedingCases of patientsHeterogeneous group of conditionsGroup of conditionsSignificant bleedingDiagnostic yieldDiagnostic dilemmaPlatelet disordersBleeding disordersEvaluating patientsPatient cohortMolecular pathogenesisMass cytometryHeterogeneous groupPatientsMultimodal approachBleedingImprove patient careDiagnosisDisordersPatient careGenetic sequencesLaboratory testing approachPotential utility
2023
Heidenhain variant of Creutzfeldt-Jakob disease masquerading as neuromyelitis optica spectrum disorder: recognizing when apheresis is not the answer
Burke O, Jacobs J, Tormey C, Rinder H, Villalba C, Lee E, Campos J, Abels E, Yurtsever N. Heidenhain variant of Creutzfeldt-Jakob disease masquerading as neuromyelitis optica spectrum disorder: recognizing when apheresis is not the answer. Lab Medicine 2023, 55: 520-523. PMID: 38142129, DOI: 10.1093/labmed/lmad107.Peer-Reviewed Original ResearchNeuromyelitis optica spectrum disorderCreutzfeld-Jakob diseaseOptica spectrum disorderHeidenhain variantBilateral vision lossTherapeutic plasma exchangeReal-time quaking-induced conversionCreutzfeldt-Jakob diseaseImmunosuppressive therapyVisual disturbancesPlasma exchangeNeurocognitive symptomsTreatment modalitiesVision lossHospice careSpectrum disorderRare formPreliminary diagnosisDiseaseDiagnosisDisordersEarly stagesPatientsApheresisTherapyOptimizing Donor Chimerism Threshold for Next-Generation Sequencing Monitoring of Measurable Residual Disease Post-Allogeneic Stem Cell Transplantation for Myeloid Neoplasms
Puzo C, Tormey C, Rinder H, Siddon A. Optimizing Donor Chimerism Threshold for Next-Generation Sequencing Monitoring of Measurable Residual Disease Post-Allogeneic Stem Cell Transplantation for Myeloid Neoplasms. Transplantation And Cellular Therapy 2023, 29: 459.e1-459.e4. PMID: 37062510, DOI: 10.1016/j.jtct.2023.04.005.Peer-Reviewed Original ResearchConceptsAllogeneic stem cell transplantationStem cell transplantationDonor chimerismCell transplantationNGS testingPost allogeneic stem cell transplantationMeasurable residual diseaseNext-generation sequencingAcute myeloid leukemiaConditioning regimenRelated donorsMyelodysplastic syndromeResidual diseaseValidation cohortMyeloid leukemiaMyeloid neoplasmsNGS panelLogistic regressionPatientsChimerismSignificant predictorsCharacteristic curveTransplantationRegimenConservative threshold
2021
Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection
Ma L, Sahu S, Cano M, Kuppuswamy V, Bajwa J, McPhatter J, Pine A, Meizlish M, Goshua G, Chang C, Zhang H, Price C, Bahel P, Rinder H, Lei T, Day A, Reynolds D, Wu X, Schriefer R, Rauseo A, Goss C, O’Halloran J, Presti R, Kim A, Gelman A, Dela Cruz C, Lee A, Mudd P, Chun H, Atkinson J, Kulkarni H. Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. Science Immunology 2021, 6: eabh2259. PMID: 34446527, PMCID: PMC8158979, DOI: 10.1126/sciimmunol.abh2259.Peer-Reviewed Original ResearchConceptsSevere SARS-CoV-2 infectionSARS-CoV-2 infectionIntensive care unitComplement activationRespiratory failureEndothelial injuryCOVID-19Non-COVID cohortPersonalized clinical trialsAcute respiratory failureInvasive mechanical ventilationSevere COVID-19Tertiary care centerAlternative complement pathwayICU admissionCritical illnessCare unitMechanical ventilationRisk prognosticationWashington University SchoolWorse outcomesCare centerClinical trialsHigh riskPatients
2020
Criteria for Ordering Myeloid Neoplasm Next-Generation Sequencing to Optimize Personalized Patient Care and Cost
Gisriel S, Rinder H, Siddon A. Criteria for Ordering Myeloid Neoplasm Next-Generation Sequencing to Optimize Personalized Patient Care and Cost. Blood 2020, 136: 39-40. DOI: 10.1182/blood-2020-139035.Peer-Reviewed Original ResearchNext-generation sequencingNGS testingNGS testsAML/MDSEvidence-based indicationsPatients' emotional distressCancellation criteriaMedicaid Services reimbursementPersonalized patient careClinical suspicionPathologic diagnosisMedical recordsClinical indicationsClinical trialsChimerism statusUnnecessary testingMDS progressionPatient carePathogenic variantsMolecular findingsUnknown significancePatientsPathogenic mutationsService reimbursementMolecular diagnostic laboratoriesAcute kidney injury is associated with reversible platelet dysfunction in hospitalized patients with decompensated cirrhosis
Zanetto A, Rinder H, Deng Y, Ciarleglio M, Wilson F, Bulato C, Simioni P, Garcia-Tsao G. Acute kidney injury is associated with reversible platelet dysfunction in hospitalized patients with decompensated cirrhosis. Digestive And Liver Disease 2020, 52: e13. DOI: 10.1016/j.dld.2019.12.031.Peer-Reviewed Original Research
2013
Chapter 62 Platelet Transfusion Medicine
Perrotta P, Parsons J, Rinder H, Snyder E. Chapter 62 Platelet Transfusion Medicine. 2013, 1275-1303. DOI: 10.1016/b978-0-12-387837-3.00062-6.Peer-Reviewed Original ResearchPlatelet transfusionsThrombocytopenic patientsTransfusion-related acute lung injuryTransfusion-transmitted viral infectionsAdverse effectsAcute lung injuryCommon adverse effectsPlatelet transfusion therapyLung injuryTransfusion therapyThrombocytopenic bleedingBlood therapyTransfusion reactionsBlood productsAllergic reactionsClinical experienceViral infectionTransfusionTransfusion medicineWhole bloodSeptic reactionsBleedingCell separatorPatientsTherapy
2006
Cardiac surgery in a patient with heparin-induced thrombocytopenia--cautions with use of the direct thrombin inhibitor, argatroban.
Kurup V, Transue S, Wu Y, Rinder HM, Barash P, Dewar M. Cardiac surgery in a patient with heparin-induced thrombocytopenia--cautions with use of the direct thrombin inhibitor, argatroban. Connecticut Medicine 2006, 70: 245-50. PMID: 16768071.Peer-Reviewed Original ResearchConceptsDirect thrombin inhibitorCardiopulmonary bypassCardiac surgeryThrombin inhibitorsCoronary bypass graft surgeryBypass graft surgeryAortic valve replacementNumber of patientsPresent case reportGraft surgeryValve replacementCase reportPharmacologic basisBlood productsHeparin substitutePatientsSurgeryArgatrobanPrevious exposurePertinent reportsHeparinThrombocytopeniaSubstantial numberInhibitorsReport
1999
Optimal dosing and triggers for prophylactic use of platelet transfusions
Rinder H, Arbini A, Snyder E. Optimal dosing and triggers for prophylactic use of platelet transfusions. Current Opinion In Hematology 1999, 6: 437. PMID: 10546800, DOI: 10.1097/00062752-199911000-00015.Peer-Reviewed Original ResearchConceptsProphylactic platelet transfusionsPlatelet transfusionsPlatelet transfusion guidelinesPlatelet transfusion practicesPlatelet transfusion supportAdequate platelet inventoryTransfusion intervalTransfusion guidelinesTransfusion supportMyeloablative therapyOptimal dosingTransfusion practiceProphylactic useThrombocytopenic patientsOutpatient supportPatient outcomesInpatient settingPlatelet dosePlatelet dosesTransfusionSmall dosesPlatelet inventoryPatientsDosesRecent studies
1998
Anti-C5 single chain antibody therapy blocks complement & leukocyte activation and reduces myocardial tissue damage in CPB patients
Rollins S, Fitch J, Shernan S, Rinder C, Rinder H, Smith B, Collard C, Stahl G, Alford B, Li L, Matis L. Anti-C5 single chain antibody therapy blocks complement & leukocyte activation and reduces myocardial tissue damage in CPB patients. Molecular Immunology 1998, 35: 397. DOI: 10.1016/s0161-5890(98)90798-2.Peer-Reviewed Original Research
1997
Activated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers
Grossman D, Heald P, Wang C, Rinder H. Activated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers. Journal Of The American Academy Of Dermatology 1997, 37: 409-413. PMID: 9308555, DOI: 10.1016/s0190-9622(97)70141-5.Peer-Reviewed Original ResearchConceptsVenous leg ulcersFactor V Leiden mutationV Leiden mutationFactor V LeidenAnticardiolipin antibodiesLeg ulcersLeiden mutationV LeidenVenous leg ulcerationCommon risk factorsPartial thromboplastin timeAPC resistanceEnzyme-linked immunosorbentProtein C resistanceConsecutive patientsHypercoagulable stateLeg ulcerationVenous thrombosisRisk factorsSkin ulcerationThromboplastin timeGeneral populationPatientsUlcersLow APC ratioActivated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers
Grossman D, Heald P, Wang C, Rinder H. Activated protein C resistance and anticardiolipin antibodies in patients with venous leg ulcers. Journal Of The American Academy Of Dermatology 1997, 37: 409-413. DOI: 10.1016/s0190-9622(18)30738-2.Peer-Reviewed Original ResearchVenous leg ulcersFactor V Leiden mutationV Leiden mutationFactor V LeidenAnticardiolipin antibodiesLeg ulcersLeiden mutationV LeidenVenous leg ulcerationCommon risk factorsPartial thromboplastin timeAPC resistanceEnzyme-linked immunosorbentProtein C resistanceConsecutive patientsLeg ulcerationVenous thrombosisRisk factorsSkin ulcerationThromboplastin timeGeneral populationPatientsUlcersMethods TwentyLow APC ratio
1992
The Significance of Platelets with Increased RNA Content (Reticulated Platelets) A Measure of the Rate of Thrombopoiesis
Ault K, Rinder H, Mitchell J, Carmody M, Vary C, Hillman R. The Significance of Platelets with Increased RNA Content (Reticulated Platelets) A Measure of the Rate of Thrombopoiesis. American Journal Of Clinical Pathology 1992, 98: 637-646. PMID: 1281383, DOI: 10.1093/ajcp/98.6.637.Peer-Reviewed Original ResearchConceptsPlatelet-associated immunoglobulinsRate of thrombopoiesisThrombocytopenic patientsAbsolute numberSignificance of plateletsSubset of patientsNucleic acid contentAnti-platelet antiserumStudies of micePeripheral destructionPlatelet countReticulocyte responseSubnormal levelsNormal rangePatientsAverage absolute numberFlow cytometric measurementsThrombopoietic responseNormal levelsPlatelet increaseElevated levelsFluorescent dye thiazole orangeImmunoglobulinPlateletsCytometric measurements
1991
Platelet Activation and Aggregation during Cardiopulmonary Bypass
Rinder C, Bohnert J, Rinder H, Mitchell J, Ault K, Hillman R. Platelet Activation and Aggregation during Cardiopulmonary Bypass. Anesthesiology 1991, 75: 388-393. PMID: 1716077, DOI: 10.1097/00000542-199109000-00002.Peer-Reviewed Original ResearchConceptsCardiopulmonary bypassPlatelet activationPlatelet aggregationExtracorporeal circulationEarly postoperative periodAlpha-granule releaseGMP-140 expressionPlatelet factor 4Granule membrane protein-140Alpha-granule membrane proteinPlatelet surface membranePostoperative periodPlatelet dysfunctionPlasma concentrationsIndividual patientsBypassFlow cytometryPlatelet defectsGranule productsMonoclonal antibodiesProtein 140Factor 4PlateletsPatientsAggregation defectProgressive platelet activation with storage: evidence for shortened survival of activated platelets after transfusion
Rinder H, Murphy M, Mitchell J, Stocks J, Ault K, Hillman R. Progressive platelet activation with storage: evidence for shortened survival of activated platelets after transfusion. Transfusion 1991, 31: 409-414. PMID: 1710840, DOI: 10.1046/j.1537-2995.1991.31591263195.x.Peer-Reviewed Original ResearchConceptsPercentage of plateletsPlatelet activationNormal subjectsProgressive platelet activationThrombocytopenic cancer patientsPlatelet concentrate transfusionAlpha-granule membrane protein-140Significant platelet activationConcentrate transfusionPlatelet incrementCancer patientsPlatelet recoveryThrombocytopenic patientsAutologous plateletsPosttransfusion recoveryFlow cytometryStandard blood bank conditionsGMP-140Protein 140PlateletsTransfusionPlatelet surfacePatientsSuch activationDay of collection
1990
In Vitro and In Vivo Evaluation of Platelet Transfusions Administered Through an Electromechanical Infusion Pump
Snyder E, Rinder H, Napychank P. In Vitro and In Vivo Evaluation of Platelet Transfusions Administered Through an Electromechanical Infusion Pump. American Journal Of Clinical Pathology 1990, 94: 77-80. PMID: 2360566, DOI: 10.1093/ajcp/94.1.77.Peer-Reviewed Original ResearchConceptsPlatelet transfusionsInfusion pumpGravity infusionPlatelet concentratesVivo platelet recoveryBeta-thromboglobulin releaseAdult patientsOncology patientsClinical benefitThrombocytopenic patientsPlatelet recoveryTransfusion reactionsCount incrementCell countPatientsInfusion pump systemPlatelet damageInfusion systemVivo evaluationTransfusionSignificant differencesLDH dischargeMorphology scoreInfusionHours
1988
Impact of unusual gastrointestinal problems on the treatment of tricyclic antidepressant overdose
Rinder H, Murphy J, Higgins G. Impact of unusual gastrointestinal problems on the treatment of tricyclic antidepressant overdose. Annals Of Emergency Medicine 1988, 17: 1079-1081. PMID: 3177998, DOI: 10.1016/s0196-0644(88)80449-9.Peer-Reviewed Original ResearchConceptsTricyclic antidepressant overdoseAntidepressant overdoseGastric bypass proceduresCharcoal administrationEsophageal spasmOrogastric tubeFunctional obstructionSecond patientUnreported complicationBypass proceduresFirst patientTricyclic antidepressantsGastrointestinal abnormalitiesGastrointestinal problemsPatientsRapid absorptionOverdoseSpasmAntidepressantsComplicationsNitroglycerinObstructionTherapyAbnormalitiesAdministrationSeptic Anaerobic Jugular Phlebitis with Pulmonary Embolism: Problems in Management
Bach M, Roediger J, Rinder H. Septic Anaerobic Jugular Phlebitis with Pulmonary Embolism: Problems in Management. Clinical Infectious Diseases 1988, 10: 424-427. PMID: 3375694, DOI: 10.1093/clinids/10.2.424.Peer-Reviewed Original ResearchConceptsGram-negative bacillary bacteremiaMultiple septic pulmonary emboliSeptic pulmonary emboliSurgical venous ligationEpisodes of pharyngitisHealthy young menUniocular blindnessVein involvementAntibiotic therapyPulmonary emboliFacial swellingPulmonary embolismSystemic anticoagulationVenous ligationEarly recognitionTherapeutic measuresEarly signsPhlebitisTherapyPatientsYoung menProptosisBacteremiaEmbolizationPharyngitis